NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01063179,"Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients",https://clinicaltrials.gov/study/NCT01063179,,COMPLETED,"The proposed study will evaluate whether the combination of VELCADE, Thalidomide , Melphalan and Prednisone (V-MPT), as induction treatment for newly diagnosed elderly MM patients, improves outcomes compared to the combination VELCADE-MP.",NO,Multiple Myeloma,"DRUG: Bortezomib, Melphalan, Prednisone, Thalidomide|DRUG: Bortezomib, Melphalan, Prednisone","Determine whether the V-MPT combination improves progression free survival (PFS), Approximately 24 months","Determine whether the VMPT combination improves:Response rate, Overall Survival rate, Time and duration of response, Assess the safety, Assess the prognostic factors, Approximately 24 months",,Fondazione EMN Italy Onlus,,ALL,OLDER_ADULT,PHASE3,511,OTHER,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,GIMEMA-MM-03-05|2005-004745-33,2006-05,2014-07,2014-07,2010-02-05,,2023-06-29,"A.O.U. S. Giovanni Battista, Torino, 10126, Italy",
